Affordable Access

deepdyve-link
Publisher Website

Safety and tolerability of 68Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pancreatic ductal adenocarcinoma: the first in-human use.

Authors
  • Hodolic, Marina1, 2
  • Wu, Wen-Yu3
  • Zhao, Zhenyu3
  • Yu, Fei3
  • Virgolini, Irene4
  • Wang, Feng3
  • 1 Nuclear Medicine Research Department, IASON, Graz, Austria. [email protected] , (Austria)
  • 2 Department of Nuclear Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic. [email protected] , (Czechia)
  • 3 Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. , (China)
  • 4 Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria. , (Austria)
Type
Published Article
Journal
European Journal of Nuclear Medicine
Publisher
Springer-Verlag
Publication Date
Apr 01, 2021
Volume
48
Issue
4
Pages
1229–1234
Identifiers
DOI: 10.1007/s00259-020-05045-w
PMID: 33006657
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Over the last decades, multiple peptide receptors were recognized as potential diagnostic and therapeutic targets in nuclear medicine. 68Ga-NT-20.3 radiopharmaceutical has been developed for diagnosis of neurotensin receptors. High neurotensin receptor expression has been observed in pancreatic ductal adenocarcinoma as well as various malignancies. Until now, 68Ga-labelled NT ligand was successfully applied in in vitro as well as in animal model. Our study is the first in-human study on safety and tolerability of 68Ga-NT-20.3. Subjects were intravenously injected with 2.5 MBq of 68Ga-DOTA-NT-20.3 per kilogramme of body weight, and series of PET images were acquired at 5-25 min, 25-45 min, 45-65 min, and 65-85 min after 68Ga-NT-20.3 injection. Vital parameters are as follows: systolic and diastolic blood pressure (mmHg), heart rate (heart beat/min), respiratory rate (number of breaths/min), ECG, and body temperature (°C) were checked before, immediately after, and 3 h after 68Ga-NT-20.3 injection. The organ-absorbed doses were calculated for the self-dose and cross-dose from each organ region using the OLINDA/EXM version 2.1 software. The results from this small trial demonstrate that PET radiopharmaceutical 68Ga-NT-20.3 is safe and well tolerated.

Report this publication

Statistics

Seen <100 times